Document Detail

Protection by short-chain fatty acids against 1-beta-D-arabinofuranosylcytosine-induced intestinal lesions in germfree mice.
MedLine Citation:
PMID:  10103207     Owner:  NLM     Status:  MEDLINE    
In germfree mice, the administration of short-chain fatty acids (SCFA) protected the intestinal mucosa from damage produced by 1-beta-D-arabinofuranosylcytosine (Ara-C). Animals receiving SCFA and Ara-C had intestinal morphologies closer to normal than the control animals, which had severe intestinal lesions. We concluded that orally administrated SCFA reduce intestinal lesions, improving the mucosa pattern of the small intestine and colon.
M G Ramos; E A Bambirra; J R Nicoli; D C Cara; E C Vieira; J Alvarez-Leite
Related Documents :
8125387 - Effects of short chain fatty acids on gut morphology and function.
16289777 - Enhancement of intestinal absorption of poorly absorbed hydrophilic compounds by simult...
7349487 - Effect of fermentable carbohydrates on volatile fatty acids, ammonia and mineral absorp...
18073277 - Use of phytogenic products as feed additives for swine and poultry.
7113547 - Influence of anti-rheumatic drugs on the activity of collagenolytic cathepsin in hepati...
10859157 - Identification and characterization of n-acetylcysteine conjugates of valproic acid in ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Antimicrobial agents and chemotherapy     Volume:  43     ISSN:  0066-4804     ISO Abbreviation:  Antimicrob. Agents Chemother.     Publication Date:  1999 Apr 
Date Detail:
Created Date:  1999-06-03     Completed Date:  1999-06-03     Revised Date:  2013-04-17    
Medline Journal Info:
Nlm Unique ID:  0315061     Medline TA:  Antimicrob Agents Chemother     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  950-3     Citation Subset:  IM    
Departamento de Bioquímica e Imunologia, ICB-UFMG, Belo Horizonte, MG, Brazil.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
Cytarabine / adverse effects*
Disease Models, Animal
Fatty Acids, Volatile / adverse effects,  therapeutic use*
Fatty Liver / chemically induced
Intestinal Diseases / chemically induced,  pathology,  prevention & control*
Intestinal Mucosa / drug effects,  pathology
Protective Agents / adverse effects,  therapeutic use*
Reg. No./Substance:
0/Fatty Acids, Volatile; 0/Protective Agents; 147-94-4/Cytarabine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Alterations in GyrA and ParC associated with fluoroquinolone resistance in Enterococcus faecium.
Next Document:  Mutations in the gyrA, parC, and parE genes associated with fluoroquinolone resistance in clinical i...